Good for you Craig… that you can keep the door open for
Good for you Craig… that you can keep the door open for the 13d group. I am way past all the misinformation and out right lies that have been pushed by the bashers who I believe are more than just average stock holders. I am sure we have many paid basher pushing their agenda not just here but on all social media and chat boards. This is a big production that they have tried to accomplish. I feel that they were coarse and abrasive and just didn’t function in a way that garnered enough support. I think they have failed in their bid to take over the company. This proxy card that I don’t remember the color of will let them know in a day or so that they have ultimately failed.
This deception and effort of the 13d group doesn’t bode well. It just wont matter what the can provide as a plan for me now that I would even consider changing sides. It’s just to late for them to bring something to the table that would be worthy. They have shown their true colors and honesty isn’t one attribute they have. They just don’t have anything I would be excited about. Their leadership from top to bottom isn’t impressive and lack any experience needed in a biotech. Last I checked we are a biotech and the 13d people that might have some experience were former employees that sued us and cost us millions. Just the wrong type of people to put forward as someone we need or want. Are these former employees looking for revenge?
I feel that the 13d group has put hate as their number one priority to inflict on our company and that’s just not ok. It’s not ok to push a bashing agenda and be rewarded with followers. People are not fooled by such terrible actions. Nobody aspires to be a basher and hopes to be liked for it. We can’t take a chance on an inexperienced new management that is clueless to everything going on with partnerships and relationships with people all over the world and will take many months to get up to speed figure it all out. Now is not the time to allow a new group to take the reins on a company on the cusp of great things.
There is so many positive catalysts happening in the next few months. I feel fortunate to be invested in this company and see the growth of this management to learn the lessons they have and apply the knowledge to the new trials. We are almost there and don’t need any help to get there. Especially from a group I wouldn’t trust them as far as I could throw them.
Everyone should really ask themselves who is more trust worthy? A management with a plan to trial 10 indications a year and grow into our own big Pharma or a group that doesn’t have a plan. Won’t show us a plan and never had a plan they would ever show us. It’s really quite scary and not very genuine to believe someone that has no apparent leadership or direction to show us something now. Our management has been straight forward and left no doubt in their plan or their new presentation. I approve of our current direction and future direction and see great things happening. Why take a chance on a group that could screw us over. That just doesn’t make sense. I won’t trust someone like the 13d group with my money. They have done nothing to impress us or do we expect them to. The big issue here is trust… who has earned my trust. I can tell you I have absolutely no trust in the 13d group.
16
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Top 5 Most Recently Viewed Articles
Veriforce Expands Its Mission with Highwire Acquisition The combined expertise delivers stronger safety, compliance, and financial risk management for construction projects worldwide Veriforce, a leader in contractor management and supply chain risk management, has recently announced its acquisition of Highwire. This acquisition is significant in the realm of contractor...
Continue Reading
Tyra Biosciences Receives Analyst Upgrade BofA Securities has recently upgraded Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology firm specializing in the creation of next-generation precision medicines. This upgrade highlights investor optimism as the company demonstrates promising results in its drug development process. Focus on Precision Medicine in...
Continue Reading
ConnX landed a hefty contract back in 2024 with the Southeastern Pennsylvania Transportation Authority (SEPTA) for a major overhaul of their communications network. The deal’s supposed to create a seamless communication experience, but you know how these things go—desks are skeptical about the actual impact. SEPTA's Communication Crisis: Is Cloud the Answer? SEPTA,...
Continue Reading
Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...
Continue Reading
Cargotec's Board of Directors Restructuring Meeting Highlights Cargotec Corporation has made significant decisions during its recent Board of Directors meeting, as it prepares for exciting changes ahead. Notably, the Board has elected Jukka Moisio as Chair, continuing a strong leadership footprint. Alongside him, Casimir Lindholm has been appointed Vice Chair, effective...
Continue Reading